🔗 Share this article

While the US continues making unprecedented adjustments to its immunization schedules, an unexpected name has surfaced somewhat surprisingly: Høeg, a Danish American sports medicine doctor and public health researcher who initially gained attention by questioning coronavirus shots throughout the global health crisis and has concentrated on potential fatalities after Covid immunization in her recent tenure at the Food and Drug Administration.

Scheduled Shifts to Childhood Immunization Schedule

Health officials were set to reveal radical changes to the childhood immunization program recently, aligning the US with the Danish immunization schedule, it is understood – a significant shift that would place the US at odds with a large portion of the international standard with insufficient data for improved outcomes. The announcement has been pushed back until the new year.

Rather than the top vaccines chief, Dr. Høeg is scheduled to present at the gathering. She was recently named acting director of the FDA’s drug evaluation center, the fifth appointee to lead the division this year.

A New Direction at the FDA

The acting appointment could signify a closer partnership between the drug and vaccine branches as Dr. Høeg and Prasad consolidate power at the FDA – and it suggests a increased emphasis upon dismantling long-standing immunizations at the FDA.

Dr. Høeg has repeatedly called for halting some childhood vaccine recommendations in the US in order to be more similar to Denmark's approach, a country with comprehensive healthcare and a number of inhabitants about the population of Wisconsin’s.

In her initial public appearances, she has kept her attention on vaccination policy – typically the responsibility of Dr. Prasad, chief of the FDA’s Center for Biologics Evaluation and Research (CBER) – as opposed to pharmaceutical oversight.

Concerns Over Background

The appointee has little discernible track record in pharmaceutical research, oversight or leadership, which has been typical for previous heads of the CBER. She has served at the FDA as a key advisor to the agency head and the vaccine center since spring.

“She doesn’t seem to have any of the qualifications” for running the pharmaceutical oversight division, remarked Jonathan Howard. “She has not conducted a randomized controlled trial. She is not versed in leading a sizeable institution. She lacks background in pharmaceutical oversight.”

Former heads of the center would “grasp legal statutes and the research of pharmaceutical innovation”, said a former acting FDA commissioner. “Objectively, she lacks the type of experience that previous people who led the center have had.”

The drug center has an vast workload at the FDA, she emphasized.

“Everybody just focuses on the novel medication approvals, but the generic drug division approves thousands of off-brand pharmaceuticals. There is also a biologic copycat branch, over-the-counter program and more, and each of these have to be looked after,” she said. “The thing you don’t keep your eye on, that is the part that I always told people is going to come back to haunt you.”

There is also, a major management element to the role, which manages more than 5,000 staff members. “It’s a huge management job, if you execute it properly,” Woodcock added.

Agency Reaction and Controversial Policies

When asked about concerns about Høeg’s credentials and whether this assignment represents increased cooperation among regulatory chiefs on vaccines, a press secretary said that the “concerns are based on incorrect premises”.

“Her experience aligns with the duties of her position,” the official stated, pointing to the months Dr. Høeg spent guiding the agency head on “medication safety and regulatory science, including computerized risk analysis and shot safety tracking”.

As acting director, Høeg inherits the commissioner’s new expedited review system, a controversial rapid drug-approval program that allegedly troubled her former heads. “How are these medications being selected for this fast-track system? Who is making the choices?” Dr. Howard questioned. “There is a lot of secrecy going on at the regulatory body right now.”

Broadly speaking, he stated, “the Food and Drug Administration appears to be shifting towards more relaxed regulations of most medications, aside from shots.”

Public Track Record on Immunizations

Regarding immunizations, Høeg has a more established, if troubling, past, some experts observe. She released a analysis using non-validated public submissions to estimate the rate of myocarditis after COVID-19 vaccination. She counseled the state of Florida surgeon general Dr. Joseph Ladapo, who allegedly have changed statistics to suggest COVID-19 vaccinations are pose a greater threat than they are.

Among her “wish list” for the new administration encompassed revising guidelines for recently developed shots and discontinuing “optional” vaccines, she stated after the election on a podcast. At the FDA, Høeg has according to sources suggested excluding young men from receiving Covid vaccines.

“She’s an complete true believer who begins with her conclusions and reverse-engineers to fit the science in a extremely disingenuous, fraudulent fashion,” Howard argued.

Taking Control and a “Campaign of Retribution”

Dr. Høeg joined other skeptics, {like|